Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study-Reference-Cited by-同舟云学术

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

Published:2023-10 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Romero-Laorden Nuria^ORCID,Lorente David,de Velasco Guillermo,Lozano Rebeca,Herrera Bernardo,Puente Javier,López Pedro P.,Medina Ana,Almagro Elena,Gonzalez-Billalabeitia Enrique,Villla-Guzman Jose Carlos,González-del-Alba Aránzazu,Borrega Pablo,Laínez Nuria,Fernández-Freire Ana,Hernández Amaia,Rodriguez-Vida Alejo,Chirivella Isabel,Fernandez-Parra Eva,López-Campos Fernando,Isabel Pacheco Maria,Morales-Barrera Rafael,Fernández Ovidio,Villatoro Rosa,Luque Raquel,Hernando Susana,Castellano Daniel C.,Castro Elena,Olmos David

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference15 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013

3. 223Ra therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematologic toxicity;Fosbøl;J Nucl Med,2018

4. Assessing radiographic response to 223Ra with an automated bone scan index in metastatic castration-resistant prostate cancer patients;Anand;J Nucl Med,2020

5. Consensus on molecular imaging and theranostics in prostate cancer;Fanti;Lancet Oncol,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer;Frontiers in Oncology;2024-05-07